The Bevacizumab Skip in Atezolizumab plus Bevacizumab for Hepatocellular Carcinoma
Systemic therapy for unresectable Hepatocellular Carcinoma (u-HCC) has advanced in recent years, particularly immunotherapy. Atezolizumab plus bevacizumab has shown significant survival benefit in u-HCC, and recent AASLD guidelines recommend this regimen as a first-line option.
Authors
- Tomokazu Kawaoka (ORCID: https://orcid.org/0000-0002-1887-1096)
Publication Details
- Journal
- SciBase Gastroenterology and Hepatology
- Published
- 2024-10-09
- DOI
- https://doi.org/10.52768/scibasegastroenterolhepatol/1005
- Primary Topic
- Hepatocellular Carcinoma Treatment and Prognosis
- Type
- article
- Field-Weighted Citation Impact
- 0.00